Rein Therapeutics, Inc. RNTX
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Rein Therapeutics, Inc. (RNTX) is a healthcare company listed in the US with a market value of about $48M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -102%.
About Rein Therapeutics
Rein Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. It was profitable in 0 of the last 10 years in our data. Its share count rose by 461% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$50M | -$63M | -$16M | -$27M | -$26M | -$27M | -$29M | -$32M | -$23M | -$18M |
| Free cash flow | — | — | — | — | -$24M | -$20M | -$27M | -$32M | -$21M | — |
| EPS (diluted) | $-1.96 | $-3.51 | $-3.42 | $-6.02 | $-5.89 | $-0.61 | $-1.20 | $-2.14 | $-3.04 | $-42.35 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -236.4% | -94.6% | -13.1% | -117.0% | -47.7% | -133.1% | -112.3% | -100.8% | -38.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Rein Therapeutics pay a dividend?
Not currently.
Is Rein Therapeutics a good stock to buy?
We do not give buy or sell advice. Rein Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.